Exavir Therapeutics

Executive Summary

Exavir Therapeutics is a private biotechnology company based in Cambridge, MA, founded in 2019, that is pioneering ultra-long-acting antiviral therapies using a proprietary prodrug technology platform. The company’s initial focus is on transforming the treatment and prevention of chronic viral infections such as HIV and HBV, with the goal of enabling dosing intervals of several months. Exavir is currently in Phase 1 clinical development for its lead candidate, which represents a paradigm shift from daily oral regimens to infrequent injectable treatments. The platform’s prodrug approach is designed to achieve sustained drug concentrations in the body, potentially improving adherence and reducing viral transmission. The company operates through a combination of internal development and strategic partnerships, leveraging its technology to address significant unmet needs in global health. Despite being at an early stage, Exavir has a clear value proposition in the long-acting antiviral space, a rapidly growing market. The success of its Phase 1 trial and subsequent development will be critical for validating the platform. Key near-term catalysts include initial Phase 1 data, which could demonstrate safety and extended pharmacokinetics, as well as potential partnership or licensing deals for its HBV program. The company’s ability to execute on its clinical milestones and secure non-dilutive funding will be essential for advancing its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead HIV candidate60% success
• Q3 2026Partnership or licensing agreement for HBV program50% success
• Q2 2027Preclinical proof-of-concept data for next-generation prodrugs70% success